Program
insulin glulisine
Also written as “Insulin Glulisine”, “Insulin glulisine” and “INSULIN GLULISINE”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 380 open or running | phase 4since Aug 3, 2006 | Sep 20, 2002 | none ahead |
| ikfe-CRO | 20 open or running | phase 4since Aug 15, 2011 | Aug 15, 2011 | none ahead |
| Geropharm | 10 open or running | phase 3since Jul 9, 2025 | Jul 9, 2025 | none ahead |
| Profil Institut für Stoffwechselforschung | 10 open or running | phase 1since Aug 31, 2009 | Aug 31, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 24 studies since Sep 20, 2002.
- Jan 23, 2008Phase 4 study in Diabetes Mellitus, Type 1Sanofi · NCT00607087 · 289 enrolled · United States, Australia, Austria and more
- Apr 29, 2008Phase 3 study in AMISanofi · NCT00670228 · 34 enrolled · United States, Argentina, Brazil and more
- Aug 24, 20092 phase 4 studiesSanofi · NCT00965549, NCT00964574
- Aug 31, 2009Profil Institut für Stoffwechselforschung’s first study: phase 1 study in Diabetes MellitusNew to Profil Institut für StoffwechselforschungProfil Institut für Stoffwechselforschung · NCT00969592 · 12 enrolled · Germany
- Nov 12, 2009Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT01013571 · 493 enrolled · Canada
- Feb 25, 2010Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT01079364 · 52 enrolled · Netherlands
- Jul 8, 2010Phase 1 study in Diabetes Mellitus, Type 2Sanofi · NCT01159353 · 37 enrolled · France
- Sep 14, 20104 phase 4 studiesSanofi · NCT01203111, NCT01202474, NCT01204593 and 1 more
- Nov 3, 2010Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT01234597 · 219 enrolled · Israel
- Aug 15, 2011ikfe-CRO’s first study: phase 4 study in Diabetes Mellitus, Type 2New to ikfe-CROikfe-CRO · NCT01417897 · 12 enrolled · Germany
- Dec 5, 2011Phase 4 study in Diabetes Mellitus, Type 2ikfe-CRO · NCT01500850 · 60 enrolled · Germany
- Sep 20, 2016Phase 1 study in Type1 Diabetes MellitusSanofi · NCT02910518 · 44 enrolled · Germany
- Nov 21, 2017Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT03359837 · 384 enrolled · China
- Jul 9, 2025Geropharm’s first study: phase 3 study in Type 1 Diabetes MellitisNew to GeropharmGeropharm · NCT07070752 · 224 enrolled · Russia
TargetBeta
“Insulin receptor agonist”ChEMBL 37, by rule
Other programs on INSR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Insulin Glarginerule | Sanofi | phase 4 | 190 |
| Insulin Aspartrule | Novo Nordisk | phase 4 | 146 |
| insulin degludecrule | Novo Nordisk | phase 4 | 108 |
| Insulinrule | Pfizer | phase 4 | 50 |
| insulin icodecrule | Novo Nordisk | phase 4 | 30 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| LY3938577 | Eli Lilly | phase 2 | 3 |
Studies
All 42 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07070752Type 1 Diabetes Mellitis · Russia | 3 | Completed | Geropharm | Nov 28, 2023 | 224 |
| NCT03359837Diabetes Mellitus, Type 2 · China | 4 | Completed | Sanofi | Jun 29, 2020 | 384 |
| NCT02910518Type1 Diabetes Mellitus · Germany | 1 | Completed | Sanofi | May 3, 2017 | 44 |
| NCT01500850Diabetes Mellitus, Type 2 · Germany | 4 | UNKNOWN | ikfe-CRO | Oct 2012 | 60 |
| NCT01417897Diabetes Mellitus, Type 2 · Germany | 4 | UNKNOWN | ikfe-CRO | May 2012 | 12 |
| NCT01234597Diabetes Mellitus, Type 2 · Israel | 4 | Completed | Sanofi | Apr 2015 | 219 |
| NCT01212913Diabetes Mellitus, Type 2 · Korea, Republic of | 4 | Completed | Sanofi | May 2012 | 161 |
| NCT01204593Diabetes Mellitus, Type 1 · Algeria, Argentina, Brazil and more | 4 | Completed | Sanofi | Jan 2013 | 206 |
| NCT01203111Diabetes Mellitus, Type 2 · Algeria, Brazil, Israel and more | 4 | Completed | Sanofi | Jul 2012 | 207 |
| NCT01202474Diabetes Mellitus, Type 1 · Russian Federation | 4 | Completed | Sanofi | Oct 2012 | 100 |
| NCT01159353Diabetes Mellitus, Type 2 · France | 1 | Completed | Sanofi | Apr 2008 | 37 |
| NCT01079364Diabetes Mellitus, Type 2 · Netherlands | 4 | Terminated | Sanofi | Jul 2012 | 52 |
| NCT01013571Diabetes Mellitus, Type 2 · Canada | 4 | Completed | Sanofi | Jan 2012 | 493 |
| NCT00969592Diabetes Mellitus · Germany | 1 | Completed | Profil Institut für Stoffwechselforschung | Dec 2007 | 12 |
| NCT00965549Diabetes Mellitus, Type 2 · Australia, United Kingdom | 4 | Completed | Sanofi | Dec 2012 | 463 |
| NCT00964574Diabetes Mellitus, Type 1 · Belarus | 4 | Completed | Sanofi | Jul 2010 | 68 |
| NCT00670228AMI · United States, Argentina, Brazil and more | 3 | Terminated | Sanofi | Nov 2009 | 34 |
| NCT00607087Diabetes Mellitus, Type 1 · United States, Australia, Austria and more | 4 | Completed | Sanofi | Jun 2009 | 289 |
| NCT00539448Diabetes Mellitus, Type 1 · Bahrain, Kuwait, Qatar and more | 4 | Completed | Sanofi | Dec 2008 | 98 |
| NCT00526513Diabetes Mellitus · Egypt | 4 | Completed | Sanofi | May 2008 | 188 |
| NCT00489190Diabetes Mellitus, Type 1 · Kazakhstan | 4 | Completed | Sanofi | 45 | |
| NCT00467376Diabetes Mellitus · China | 3 | Completed | Sanofi | Jun 2008 | 485 |
| NCT00397553Diabetes Mellitus, Type 1 · Russian Federation | 3 | Completed | Sanofi | Dec 2007 | 104 |
| NCT00384085Diabetes Mellitus, Type 2 · United States | 4 | Completed | Sanofi | Mar 2010 | 588 |
| NCT00368394Diabetes Mellitus, Type 1 · Germany | 1 | Completed | Sanofi | 18 | |
| NCT00360698Diabetes Mellitus, Type 2 · United States, Russian Federation, United Kingdom | 4 | Completed | Sanofi | Aug 2008 | 106 |
| NCT00311077Diabetes Mellitus | 1 | Completed | Sanofi | Oct 2004 | |
| NCT00310297Diabetes Mellitus, Type 2 | 1 | Completed | Sanofi | Dec 2004 | |
| NCT00297583Diabetes Mellitus, Type 1 | 1 | Completed | Sanofi | May 2004 | |
| NCT00290979Diabetes Mellitus, Type 1 · Japan | 3 | Completed | Sanofi | 250 | |
| NCT00290927Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Sanofi | 390 | |
| NCT00290043Diabetes Mellitus, Type 1 | 1 | Completed | Sanofi | 20 | |
| NCT00272064Diabetes Mellitus, Type 2 · Italy | 3 | Completed | Sanofi | May 2008 | 352 |
| NCT00272012Diabetes Mellitus, Type 2 · Germany | 3 | Completed | Sanofi | Sep 2006 | 396 |
| NCT00271284Diabetes Mellitus, Type 1 · France | 3 | Completed | Sanofi | Sep 2008 | 88 |
| NCT00174668Diabetes Mellitus, Type 2 · Australia, Belgium, Czech Republic and more | 3 | Completed | Sanofi | Nov 2007 | 311 |
| NCT00135941Diabetes Mellitus · United States | 3 | Completed | Sanofi | 582 | |
| NCT00135096Diabetes Mellitus, Type 2 · United States | 3 | Completed | Sanofi | 345 | |
| NCT00135083Diabetes Mellitus, Type 2 | 3 | Completed | Sanofi | 347 | |
| NCT00135057Diabetes Mellitus, Type 2 · United States | 3 | Completed | Sanofi | 281 | |
| NCT00115570Diabetes Mellitus, Type 1 · United States | 3 | Completed | Sanofi | Nov 2006 | 572 |
| NCT00046150Diabetes Mellitus, Type 1 · France, Germany, Netherlands | 3 | Completed | Sanofi | 59 |
How it is read
Names in the registry
- “Insulin Glulisine”, 12 entries
- “Insulin glulisine”, 11 entries
- “insulin glulisine”, 8 entries
- “INSULIN GLULISINE”, 4 entries
- “INSULIN GLULISINE (HMR1964)”, 2 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 21 studies
- Diabetes Mellitus, Type 1, 16 studies
- Diabetes Mellitus, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.